Plain-English translation of NCT06248996 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether giving radiation therapy in a different way — using smaller doses delivered twice a day instead of once a day — can help treat head and neck cancer better in patients whose tumors are at higher risk of coming back. Researchers believe this approach, called hyperfractionated radiotherapy, might work better than standard radiation for these high-risk patients, and they're comparing it directly against the current standard treatment to find out.
Many patients with advanced head and neck cancer don't respond well enough to standard radiation therapy, and doctors need better ways to personalize treatment based on which patients are at highest risk. This trial aims to find out whether giving more radiation in smaller, more frequent doses can improve survival and cure rates for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either standard radiation therapy (given once daily for a total dose of 68 Gy) or the new hyperfractionated approach (given twice daily for a total dose of 83 Gy). Both groups will also have imaging scans and blood or tissue samples taken to help researchers understand what makes the treatment work better or worse. You'll be closely monitored during treatment and followed up afterward to see how well the treatment worked.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Sweden